BLS PHARMACEUTICALS LIMITED
ASX:BLSHousehold & Personal ProductsToday’s holders own 94.3% of what they think they own, once every option and right converts.
Options/rights overhang 6% of shares; 2% of shares in the money; since relisting as BLS; prior history under BXN not included
BLS PHARMACEUTICALS LIMITED is trading as BLS only since July 2026, following a rename from BXN. Every figure below covers only the period since the rename. The ordinary share count grew 0.1% between August 2026 and September 2026, to 230M shares. No capital raises were undertaken in the past 24 months, and no proposed securities issues are pending. Options and rights on issue could convert into 14M new shares, representing 6.1% of the current share count, of which 2% are in the money, with the nearest expiry in March 2027. At the June 2026 quarter, the company reported A$15.8M in available cash and positive net cash flow for the period.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 3 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 10 Sept 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 230.5M | Appendix 2A |
| 4 Sept 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 230.4M | Appendix 2A |
| 12 Aug 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 230.3M | Appendix 2A |
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered5.5M · 2.4% of sharesOptions and warrants — they convert when the share price clears their exercise price.
- Condition-triggered8.6M · 3.7% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 5.5M priced (of which 5.5M in the money), 8.6M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
At $1.18 today, 5.5M securities are in the money (2.4% of shares on issue) — a floor, because an exercise price is on record for only 39.1% of this supply. No price up to ten times today’s switches on any more priced supply.
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 8.6M (60.9% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| BLSAG | Options | Price-triggered | $0.10 | 26 Mar 2027 | 100k | Filing |
| BLSAF | Options | Price-triggered | $0.44 | 26 Mar 2027 | 1.5M | Filing |
| BLSAE | Options | Price-triggered | $0.50 | 26 Mar 2027 | 3.9M | Filing |
| BLSAC | Performance rights | Condition-triggered | — | — | 8.6M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.